Preliminary analysis of an expanded access study of the fixed-dose combination of pertuzumab (P) and trastuzumab (H) for subcutaneous injection (PH FDC SC) for at-home administration (admin) in patients (pts) with HER2-positive (HER2+) breast cancer (BC) during the COVID-19 pandemic Meeting Abstract
| Authors: | Dang, C. T.; Tolaney, S. M.; Riaz, F.; Tan, A. R.; Tkaczuk, K. H. R.; Yu, A. F.; Liu, J.; Fung, A. M.; Yang, A.; Day, B. M.; Rugo, H. S. |
| Abstract Title: | Preliminary analysis of an expanded access study of the fixed-dose combination of pertuzumab (P) and trastuzumab (H) for subcutaneous injection (PH FDC SC) for at-home administration (admin) in patients (pts) with HER2-positive (HER2+) breast cancer (BC) during the COVID-19 pandemic |
| Meeting Title: | 2022 ASCO Annual Meeting |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 40 |
| Issue: | 16 Suppl. |
| Meeting Dates: | 2022 Jun 3-7 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2022-06-01 |
| Language: | English |
| ACCESSION: | WOS:000863680300571 |
| PROVIDER: | wos |
| DOI: | 10.1200/JCO.2022.40.16_suppl.1515 |
| Notes: | Meeting Abstract: 1515 -- This meeting was also held virtually -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work